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Abstract
Background: Hepatocyte and keratinocyte growth factors are key growth factors in the process of
alveolar repair. We hypothesized that excessive alveolar destruction observed in lung emphysema
involves impaired expression of hepatocyte and keratinocyte growth factors or their respective
receptors, c-met and keratinocyte growth factor receptor. The aim of our study was to compare
the expression of hepatocyte and keratinocyte growth factors and their receptors in lung samples
from 3 groups of patients: emphysema; smokers without emphysema and non-smokers without
emphysema.
Methods: Hepatocyte and keratinocyte growth factor proteins were analysed by immunoassay
and western blot; mRNA expression was measured by real time quantitative polymerase chain
reaction.
Results: Hepatocyte and keratinocyte growth factors, c-met and keratinocyte growth factor
receptor mRNA levels were similar in emphysema and non-emphysema patients. Hepatocyte
growth factor mRNA correlated negatively with FEV1 and the FEV1/FVC ratio both in emphysema
patients and in smokers with or without emphysema. Hepatocyte and keratinocyte growth factor
protein concentrations were similar in all patients' groups.
Conclusion: The expression of hepatocyte and keratinocyte growth factors and their receptors
is preserved in patients with lung emphysema as compared to patients without emphysema.
Hepatocyte growth factor mRNA correlates with the severity of airflow obstruction in smokers.
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Background
Emphysema is one of the most important cause of respi-
ratory insufficiency with increasing mortality and morbid-
ity [1]. Lung emphysema is defined pathologically by the
destruction of alveolar walls with abnormal permanent
enlargement of the air spaces distal to the terminal bron-
chiole. Precise mechanims contributing to the destruction
of alveolar walls remain unclear. Cigarette smoking may
induce emphysema by stimulating neutrophils and alveo-
lar macrophages to produce proteases leading to the deg-
radation of the alveolar extracellular matrix and oxidant
injury contributing to alveolar destruction [2]. T lym-
phocytes contribute to the recruitment and activation of
these inflammatory cells and may be involved in the
apoptosis and destruction of alveolar epithelium [3-5].
Recent evidence of increased apoptosis of alveolar epithe-
lial and endothelial cells in emphysematous lung suggests
that primary alterations of the alveolar epithelium and
endothelium might participate in the pathogenesis of the
disease [6-8].
The alveolar epithelium is essential for maintenance of
the integrity of the alveolar spaces. Functional restoration
of the alveolar epithelium after an injury requires the pro-
liferation and migration of type 2 pneumocytes and their
differentiation into type 1 pneumocytes, a tightly regu-
lated phenomenon. Growth factors have been shown to
control both phases of the process [9-12]. Among these
factors, the hepatocyte growth factor (HGF), a het-
erodimeric protein obtained through the cleavage of an
inactive precursor, called 90-kD proHGF, and the kerati-
nocyte growth factor (KGF, also named fibroblast growth
factor-7, FGF-7) have been identified as key factors in the
process of alveolar repair, both in acute or chronic condi-
tions [13-15]. HGF and KGF respectively act through spe-
cific receptors c-met, a membrane bound tyrosine kinase
[16] and FGFR2IIIb, also named KGF-R [17]. HGF and
KGF productions by lung fibroblasts from emphysema
have been shown to be reduced when compared with con-
trols [18]. Recently, Shigemura et al reported that
decreased HGF expression due to a failure in sustained
endogenous production after injury was associated with
emphysema-related histopathologic and physiological
changes in a rat model of elastase-induced emphysema
[19]. In this animal model, HGF could have a therapeutic
effect [20,19].
We hypothesized that a defective expression of growth fac-
tors involved in human alveolar epithelium repair such as
HGF and KGF or their specific receptors might participate
in the pathophysiology of lung emphysema. We therefore
evaluated the expression of HGF, KGF, and their receptors
c-met and KGF-R in lung biopsies from patients with
emphysema and from non-emphysema patients, accord-
ing to their smoking status.
Methods
This study was approved by the ethics committee of Saint
Germain-en-Laye hospital.
Patients
Lung samples were obtained during surgery in adult
patients (>18 years) from Beaujon university hospital
(Clichy, France) and from Bichat university hospital
(Paris, France).
Patients with lung emphysema
Seventeen patients with radiographically defined emphy-
sema (E group) were included. All patients were active or
ex-smokers (Table 1). CT-scan, pulmonary function tests
and  α1-AT deficiency were systematically documented.
Patients with α1-AT deficiency were excluded. They
underwent bullectomy (n = 3), lobectomy (n = 4), lung
transplantation (n = 3) or lung volume reduction (n = 7).
Pulmonary function tests demonstrated mild to severe air-
flow obstruction and lung distension (Table 2). Tissue
samples were taken from the resected parenchyma in a
macroscopically emphysematous region. Nine patients
with emphysema were receiving corticosteroids, either
oral (n = 2) and/or inhaled (n = 8). In all patients, lung
emphysema was suspected on CT-scan and confirmed by
the pathological examination of lung resection samples.
The severity of emphysema was approached through pul-
monary function abnormalities.
Table 1: Clinical characteristics of patients with and without emphysema
Emphysema (E) Non-emphysema 
Smokers (S)
Non-emphysema Non-
Smokers (NS)
Between groups 
differences
n 1 781 0
Age (yr) 60 ± 7.4 55.8 ± 11.2 52.7 ± 19.4 ns
Sex ratio F/M 1/16 0/8 2/8 ns
Smoking (Pack.yr) 51 ± 21.4* 33.3 ± 14.8 0 p < 0.001
Time since smoking cessation (yearrs) 7.0 ± 7.1 10 (n = 1) Non relevant Non relevant
Active smokers/ex-smokers 7/10 7/1 0/0 p < 0.001
*: vs S, p < 0.05; as assessed by Mann-Whitney U-test. ns: non significant.BMC Pulmonary Medicine 2005, 5:13 http://www.biomedcentral.com/1471-2466/5/13
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Non-emphysema patients
Normal tissue was obtained from 18 non-emphysema
patients. Eight patients were smokers (non-emphysema
smoker, S) and 10 were non-smokers (non-emphysema
non-smoker, NS). S patients were undergoing surgery for
the resection of a localised primary lung carcinoma (n =
7) or a benign lesion (n = 1). NS patients were undergoing
surgery for the resection of a localised primary lung carci-
noma (n = 3), lung metastases (n = 2) or a benign lesion
(n = 5). Tissue samples were taken at a site distant from
the pathological process and without macroscopical and
microscopical evidence of emphysema. S patients had
mild to moderate alterations of pulmonary functions tests
(table 2). Increased cumulative tobacco exposure was
observed in the E group as compared with the S group
(Table 1). No difference was observed between groups for
age and sex ratio (Table 1). Two patients without emphy-
sema (S group) received inhaled corticosteroids.
Processing of lung samples
Lung tissue fragments (about 0.2 cm3) were immediately
frozen in liquid N2 and stored at -80°C until RNA and
protein analysis. The histopathology of biopsies was eval-
uated on paraffin-embedded sections to verify the features
of emphysema or normal lungs. The concentration of pro-
teins in biopsies was evaluated from 100 mg of lung
samples homogenised with 0.5 ml PBS containing 200
µM phenylmethylsulfonyl fluoride, 1 mg/ml leupeptin
and 1 mg/ml aprotinin. The homogenates were centri-
fuged at 10,000 g for 10 min at 4°C to remove tissue frag-
ments and the supernatants were collected and stored at -
80°C until measurement.
Quantitative analysis of mRNA expression
Total RNA was extracted from frozen lung tissue and
reverse transcribed. Each sample was analysed by reverse
transcriptase-real-time polymerase chain reaction (RT-
PCR) with specific primers (table 3) to quantify the
expression of mRNA of HGF, KGF, c-met and KGF-R as
described previously [21].
HGF and KGF concentration in lung homogenates
The proteins HGF and KGF (Quantikine®, R&D Systems;
respective detection limits were 40 and 15 pg/ml for HGF,
KGF) were measured in lung homogenates from 26 out of
35 patients when enough lung sample was available (13
E, 5 S, 8 NS).
HGF western blotting
Lung homogenates from 4 patients (2 patients with
emphysema and 2 patients without emphysema) were
examined by Western blotting as previously described
[22].
Statistical analysis
Data were analysed by Statview software (Abacus Con-
cepts, Inc.) and displayed as mean ± SD. Between-group
differences were first assessed by non-parametric analysis
of variance (Kruskal-Wallis test). In the case of global sig-
nificant difference, between two groups comparisons were
assessed by the non-parametric Mann-Whitney U-test.
Correlations were assessed by the Spearman's rank order
test. Categorical data were analysed using the Chi-squared
test. A p value < 0.05 was regarded as significant.
Results
Lung expression of KGF and KGF receptor
KGF mRNA (figure 1A) and KGF protein (figure 1C) were
detected in the lungs of all patients. No difference was
observed according to the presence of emphysema, and
the smoking status.
KGF-R mRNA (figure 1B) was detected in the lungs of all
patients. A considerable variability was observed in KGF-
R transcript levels in patients with or without emphysema.
No difference was observed according to the presence of
emphysema and the smoking status.
Table 2: Pulmonary function tests of patients with and without emphysema.
Emphysema (E) Non-emphysema 
Smokers (S)
Non-emphysema Non-
Smokers (NS)
Between groups 
differences
n 1 781 0
FEV1 % predicted value (% pred) 41.7 ± 26.6 *,† 71 ± 21.3 82 ± 11.1 p < 0.001
FEV1/FVC 48.7 ± 13.9 *,† 67.6 ± 14.8† 86.9 ± 11.6 p < 0.001
RV (%pred) 211.6 ± 69.4 *,† 123 ± 19.7 88 ± 23.9 p < 0.001
TLC (%pred) 121.5 ± 17.8 *,† 100 ± 10.4 † 83 ± 13.5 p < 0.001
PaO2 (mmHg) 69.7 ± 10.1 *,† 81 ± 15.8 85.2 ± 7.6 p < 0.005
PaCO2 (mmHg) 41.3 ± 5 38.7 ± 7.7 41.8 ± 2.6 ns
*: vs S, p < 0.01; †: vs NS, p < 0.01; as assessed by Mann-Whitney U-test. ns: non significant
PaO2: arterial oxygen pressure, PaCO2: arterial carbon dioxide pressure, FEV1: forced expiratory volume in one second, RV: residual volume, FVC: 
forced vital capacity, TLC: total lung capacity.BMC Pulmonary Medicine 2005, 5:13 http://www.biomedcentral.com/1471-2466/5/13
Page 4 of 8
(page number not for citation purposes)
KGF mRNA, KGF protein and KGF-R mRNA did not cor-
relate with age, cumulative tobacco exposure, period since
smoking cessation, use of inhaled corticosteroids, pulmo-
nary function tests and arterial blood gases.
Lung expression of HGF and HGF receptor
Although a considerable variability of HGF mRNA expres-
sion was observed, no difference was found between
emphysema and non-emphysema groups (figure 2A). In
emphysema patients, HGF mRNA correlated positively
with total lung capacity (TLC) (Rho = 0.51, p = 0.04, n =
17) and negatively with forced expiratory volume in one
second (FEV1) (Rho = -0.53, p = 0.03, n = 17) and FEV1/
FVC (forced vital capacity) (Rho = -0.54, p = 0.03, n = 17).
When all smokers were studied together (smokers with or
without emphysema), again, significant correlations
between HGF mRNA and FEV1 (Rho = -0.53, p = 0.009, n
= 25), and FEV1/FVC (Rho = -0.49, p = 0.017, n = 25) were
found. However, the correlation between HGF mRNA and
TLC was no more significant (Rho = 0.28, p = 0.18, n = 24)
(figure 3). There was no correlation between HGF mRNA
and cumulative tobacco exposure.
HGF protein was detected in lung homogenates from all
patients as assessed by immunoassay. HGF concentration
was not different between groups (figure 2C). HGF pro-
tein correlated positively with residual volume (RV) (Rho
= 0.43, p = 0.04, n = 24), TLC (Rho = 0.45, p = 0.03, n =
24) and negatively with FEV1/FVC (Rho = -0.45, p = 0.03,
n = 24). Although, no difference of HGF protein concen-
trations was found between patients' groups, a significant
correlation between HGF protein concentrations and
cumulative tobacco exposure was observed (Rho = 0.49, p
= 0.01, n = 26). As HGF immunoassay measured both
proHGF and mature HGF, a western blot analysis was
performed to characterize which form of HGF was present
in lung homogenates. Western blot (figure 4) demon-
strated that HGF was present mainly in the cleaved mature
form (presence of the 69-kD alpha chain) both in the
non-emphysematous and the emphysematous lungs.
HGF-R mRNA was detected in all patients. We found no
difference between groups (figure 2B). Strong correlations
were observed between HGF-R mRNA and KGF-R mRNA
(Rho = 0.82, p < 0.0001, n = 35) and between HGF mRNA
and KGF mRNA (Rho = 0.61, p = 0.004, n = 35) when all
patients were taken together.
Discussion
The involvement of KGF and HGF in lung repair has been
widely documented. Numerous studies in vitro and in
vivo have demonstrated that KGF and HGF have protec-
tive effects in experimental lung injury [15,23]. To our
knowledge, this is the first study of KGF and HGF lung
expression in human emphysema. Proteases, oxidant
injury [2], chronic inflammation [3,5] and apoptosis [6-
8] all contribute to the excessive alveolar wall destruction
observed in lung emphysema. We hypothezised that a
defect of the lung repair process might be associated with
the pathophysiology of lung emphysema. Our results
show that lung KGF mRNA and KGF protein are not
altered in emphysema. In bleomycin-induced lung injury
in rats, KGF and HGF increase in the lung [24]. A few clin-
ical studies have assessed KGF concentrations in acute
lung injury. Verghese et al reported that KGF was not
increased in lung edema fluid whereas HGF was increased
and associated with higher mortality [25]. Stern et al
reported that KGF and HGF were increased in bronchoal-
veolar lavage fluid in acute respiratory distress syndrome
and associated with a poor prognosis [13]. Recently,
Danan et al observed the highest KGF concentrations in
tracheal aspirates from premature infants who survived
without bronchopulmonary dysplasia, leading to the con-
clusion that KGF may prevent injury to lung epithelium
and enhanceits repair [26].
This study has some methodological limitations. A lim-
ited number of patients was studied in each group, espe-
cially in non emphysema groups which were mostly
composed of lung biopsies obtained at a site distant from
localised carcinoma. Furthermore, the patients could only
Table 3: Primers and PCR cycling conditions.
Primers Sequences Denaturation annealing Cycles PCR products
HGF: Forward
Reverse
5'-CAGAGGGACAAAGGAAAAGAA-3'
5'-GCAAGTGAATGGAAGTCCTTTA-3'
94°C, 15s 58°C, 60s 40 167 bp
KGF: Forward
Reverse
5'-GAACAAGGAAGGAAAACTCTATGCAA-3'
5'-AAGTGGGCTGTTTTTTGTTCTTTCT-3'
94°C, 15s 60°C, 60s 40 201 bp
HGF-R: Forward
Reverse
5'-GTTTACTTGTTGCAAGGGAGAAGACT-3'
5'-TAGGGTGCCAGCATTTTAGCA-3'
94°C, 15s 58°C, 60s 40 88 bp
KGF-R: Forward
Reverse
5'-TTAAGCAGGAGCATCGCATTG-3'
5'-AACATCCAGGTGGTACGTGTGAT-3'
94°C, 15s 60°C, 60s 40 151 bp
Ubiquitin-c: Forward
Reverse
5'-CACTTGGTCCTGCGCTTGA-3'
5'-TTTTTTGGGAATGCAACAACTTT-3'
94°C, 15s 60°C, 60s 40 105 bpBMC Pulmonary Medicine 2005, 5:13 http://www.biomedcentral.com/1471-2466/5/13
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Expression of KGF (A) and KGF-R (B) mRNA in lung tissue  from emphysema and non-emphysema patients Figure 1
Expression of KGF (A) and KGF-R (B) mRNA in lung 
tissue from emphysema and non-emphysema 
patients. Results are expressed as a ratio to Ubiquitin in 
arbitrary units. Individual and mean values (bar) are pre-
sented. No difference between groups was found. E: emphy-
sema patients; S and NS: non-emphysematous smoker and 
non-smoker patients. KGF concentrations in lung homoge-
nates were measured by immunoassay (C). The detection 
limit was 15 pg/ml. The results are displayed per 1 mg of lung 
tissue.
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Expression of HGF (A) and c-met (B) mRNA in lung tissue  from emphysema and non-emphysema patients Figure 2
Expression of HGF (A) and c-met (B) mRNA in lung 
tissue from emphysema and non-emphysema 
patients. Results are expressed as a ratio to Ubiquitin in 
arbitrary units. Individual and mean values (bar) are pre-
sented. No difference between groups was found. E: emphy-
sema patients; S and NS: non-emphysematous smoker and 
non-smoker patients. HGF concentrations in lung homoge-
nates were measured by immunoassay (C). The detection 
limit was 40 pg/ml. The results are displayed per 1 mg of lung 
tissue.
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be evaluated at one time point in the course of their dis-
ease. Inclusion of smokers without emphysema allowed
the differentiation of emphysema-related and tobacco-
related events. Because only one tissue sample from
surgically resected material was available for examination,
the expression of HGF, KGF and their receptors reflects
regional disease activity and may be unrepresentative of
the entire lung. Indeed, it is well known that emphysema
affects different lung regions to a varying extent. Moreo-
ver, we evaluated HGF and KGF in lung homogenates
only. Future studies should address the expression of HGF
and KGF in a more cell-specific fashion.
In our study, although HGF mRNA lung expression was
similar in emphysema and non emphysema patients, a
correlation was found between HGF mRNA and the
deterioration of pulmonary function tests in emphysema
patients. The correlation between airflow obstruction and
HGF mRNA level was similarly observed when all smok-
ers with or without emphysema were studied, suggesting
that emphysema was not a main determinant of HGF
mRNA level in the lung. This strong correlation between
airflow obstruction and HGF mRNA in smokers suggests
that the increase of HGF mRNA was not related to the
presence of emphysema but rather to the degree of airflow
obstruction. This observation is supported by the correla-
tion between HGF protein in lung homogenates and the
FEV1/FVC ratio in our population. These results are in
agreement with the observations of Sauleda et al, who
reported that HGF protein concentrations were increased
in broncho-alveolar lavage of patients with chronic
obstructive pulmonary disease as compared to smokers
and non-smoker controls [27]. Interestingly, the increased
Correlation between HGF mRNA and pulmonary function in  smoker patients Figure 3
Correlation between HGF mRNA and pulmonary 
function in smoker patients. The ratio of lung HGF to 
Ubiquitin mRNA was correlated with: (A) forced expiratory 
volume in one second (FEV1 % predicted), (B) FEV1/FVC 
(forced vital capacity), but not with (C) total lung capacity 
(TLC % predicted). Full circle (•): emphysema patients; open 
circle (o): smoker patients without emphysema.
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Western blot analysis of HGF in lung tissue Figure 4
Western blot analysis of HGF in lung tissue. Lung 
homogenates from 4 patients (2 patients with emphysema [E] 
and 2 non-emphysema patients [NonE]). Recombinant 
human HGF (R&D Systems: according to the manufacturer, 
rhHGF is a mixture of proHGF and cleaved mature HGF) 
was loaded and blotted in parallel. HGF was in the cleaved 
mature form as evidenced by the detection of the 69-kD α 
chain and the absence of the 90-kD proHGF form.BMC Pulmonary Medicine 2005, 5:13 http://www.biomedcentral.com/1471-2466/5/13
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lung expression of other growth factors (fibroblast growth
factors 1 and 2 and their receptors) has already been
reported in chronic obstructive pulmonary disease [28].
The mechanisms underlying the correlation between air-
flow obstruction and HGF mRNA in smokers are unclear.
Although speculative, we can propose that the mechanical
constraints applied to alveolar tissue secondary to airflow
obstruction may stimulate HGF production by alveolar
epithelial cells, since Yamamoto et al showed that
mechanical stretch induced HGF in alveolar type II cells in
vitro [29]. Furthermore, airway inflammation could con-
tribute to increase local HGF expression by neutrophils
[22] and macrophages [30]. Interestingly, Aharinejad et al
have shown that serum HGF concentrations increased at
the time of lung graft rejection, a situation associated with
airflow obstruction [31].
As HGF and KGF are key factors in the process of alveolar
repair [15], we suggest that their production might be not
adapted to the degree of alveolar injury. Indeed, in view of
the chronic lung injury observed in emphysema, one
could expect an increase of HGF and KGF expression as
observed in acute lung injury in rats [24] and in humans
[25,13]. However the direct assessment of HGF content in
lung homogenates is technically difficult. Indeed, HGF is
a heparin binding growth factor. High concentrations of
inactive precursor of HGF (proHGF) are probably bound
to proteoglycans of the extracellular matrix and may not
be assayed in the lung homogenates by immunoassay. In
this study, western blot analysis showed that HGF was
only in the mature active form, both in lung biopsies from
emphysema and non-emphysema patients.
Recently, HGF has been shown to stimulate pulmonary
regeneration and to improve pulmonary function in ani-
mal models of elastase-induced lung emphysema [20,19].
Preserved expression of HGF-R could allow therapeutic
use of growth factors in lung emphysema. Further studies
are needed to assess the therapeutic potential of HGF and
KGF in lung emphysema.
Conclusion
The main results of our study are that: i) KGF and HGF
lung expression is preserved in emphysema patients, ii)
HGF-R and KGF-R mRNA are consistently expressed in the
lung of emphysema patients and are not modified by the
smoking status, iii) HGF mRNA correlates with the sever-
ity of airflow obstruction in smokers.
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